Quadrant Capital Group’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Quadrant Capital Group’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-245	Closed	-$5K	–	2910
2022 Q3	$5K	Hold	245	–	–	﹤0.01%	2174
2022 Q2	$2K	Buy	+245	New	+$1.72K	﹤0.01%	2303
2022 Q1	–	Sell	-500	Closed	-$7K	–	2767
2021 Q4	$7K	Buy	500 +200	+67%	+$3.46K	﹤0.01%	1788
2021 Q3	$7K	Sell	300 -19	-6%	-$449	﹤0.01%	1777
2021 Q2	$8K	Buy	319 +119	+60%	+$3.2K	﹤0.01%	1697
2021 Q1	$6K	Hold	200	–	–	﹤0.01%	1757
2020 Q4	$7K	Hold	200	–	–	﹤0.01%	1602
2020 Q3	$10K	Buy	+200	New	+$8.08K	﹤0.01%	1254

Quadrant Capital Group's FMTX Position: Q4 2022 in Review

Quadrant Capital Group sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 245 shares — an estimated $5K sold.

Quadrant Capital Group first reported a position in FMTX in Q3 2020 and held it in 8 quarters. The position peaked at $10K in Q3 2020. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Quadrant Capital Group reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Quadrant Capital Group sold 245 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $5K.
Quadrant Capital Group first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Quadrant Capital Group's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $10K in Q3 2020.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.